lectins (MBL Life science)
Structured Review

Lectins, supplied by MBL Life science, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lectins/product/MBL Life science
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Complement-dependent neuroinflammation in spinal cord injury: from pathology to therapeutic implications"
Article Title: Complement-dependent neuroinflammation in spinal cord injury: from pathology to therapeutic implications
Journal: Neural Regeneration Research
doi: 10.4103/NRR.NRR-D-24-00116

Figure Legend Snippet: Overview of complement activation pathways. Created with BioRender.com. C: Complement; DAMPs: damage-associated molecular patterns; MBL: mannose-binding lectins; PAMPs: pathogen associated molecular patterns.
Techniques Used: Activation Assay, Binding Assay

Figure Legend Snippet: Triggers of complement activation after spinal cord injury. Complement pathways are activated by either the direct binding of opsonins to stressed and degenerating cells, or by antibodies that recognize DAMPs. An alternative mechanism also involves binding to CRP (an acute phase reactant). These mechanisms involve the classical and alternative pathways of C. The lectin pathway has not yet been investigated. Created with BioRender.com. C: Complement; CRP: C-reactive protein; DAMPs: damage-associated molecular patterns; MBL: mannose-binding lectins.
Techniques Used: Activation Assay, Binding Assay

Figure Legend Snippet: Inhibitors of complement activation after spinal cord injury. The figure shows the different pathways of C activation and the sites of action of different endogenous and exogenous inhibitors. (1) Inhibitors of the antibody-complement axis include genetic models of Rag1 deficiency, B-cell depletion, and Fc-gamma receptor in addition to the fusion protein B4-Crry that inhibits the bind of B4IgM to modified annexin IV. (2) Inhibitors of the classical pathway include genetic deficiency in C1q or use of C1-inhibitor (C1-INH). (3) Inhibitors of C3 convertase from all pathways include the fusion proteins B4-Crry and CR2-Crry, soluble CR1 (sCR1), and C3 deficiency. (4) Inhibition of the alternative pathway C3 convertase via factor B deficiency. (5) Inhibition of C3a-C3aR1 interaction via C3aR1 deficiency. (6) Inhibition of C5a-C5aR interaction using C5aR1 antagonist (PMX-205), C5aR1 deficiency or C5aR2 deficiency. (7) Inhibition of membrane attack complex includes C5 deficiency and C6 deficiency. Created with BioRender.com. C: Complement; DAMPs: damage-associated molecular patterns; MBL: mannose-binding lectins; PAMPs: pathogen associated molecular patterns.
Techniques Used: Activation Assay, Modification, Inhibition, Membrane, Binding Assay